Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 224 people in total — 113 in the single umbilical cord blood (UCB) transplant group and 111 in the double UCB transplant group. The trial was comparing two approaches to stem cell transplantation using donated umbilical cord blood: giving patients one cord blood unit versus two. It tracked a range of outcomes including survival, whether the new blood cells successfully established themselves in the body (called "engraftment"), and whether participants developed a condition called graft-versus-host disease (GVHD), where donated cells can react against the recipient's body. The reported data shows that, for overall survival, 73% of participants in the single transplant group and 65% in the double transplant group were alive at the time of reporting. For survival without their original disease returning, the figures were 70% (single) and 64% (double). Regarding engraftment of white blood cells (neutrophils), 89% of the single group and 88% of the double group reached that milestone, taking a reported median (middle value) of 21 days and 23 days respectively. Platelet engraftment was reported in 76% of the single group and 65% of the double group, taking a median of 58 days and 84 days. For graft-versus-host disease, the reported data shows that around 57% (single) and 56% (double) of participants developed any grade of acute GVHD, with more severe acute GVHD (grades III–IV) reported in 13% of the single group and 23% of the double group. Chronic GVHD of any type was reported in 30% (single) and 32% (double) of participants, with the more extensive form seen in 9% and 15% respectively. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 25354103) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Lymphoma Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Two partially matched umbilical cord blood (UCB) units must be available for you that meet specific tissue-matching (HLA) requirements and contain enough cells for transplant (confirm with trial site for exact details)
- You have a type of blood cancer called acute myeloid leukemia (AML) at certain stages, including high-risk first remission, second or later remission, first relapse with a low level of cancer cells, or remission with incomplete blood count recovery
- You have AML that was caused by previous cancer treatment, and your prior cancer has been in remission for at least 12 months
- You have acute lymphocytic leukemia (ALL) at certain high-risk stages in first or second remission, or any third or later remission (confirm with trial site for your specific situation)
- You have a rare type called NK cell lymphoblastic leukemia in any remission
- You have biphenotypic or undifferentiated leukemia in any remission, or in first relapse with low levels of cancer cells in the bone marrow
- You have a bone marrow condition called myelodysplastic syndrome (MDS) at any stage
- You have chronic myelogenous leukemia (CML) in the chronic or accelerated phase
- If you have leukemia affecting the brain or spinal fluid, it must have been treated and be in remission
- If you are 16 or older, you must be reasonably active and able to carry out normal daily activities (scored at least 70% on a standard health scale); if you are under 16, a similar age-appropriate scale applies
- Your heart, liver, kidneys, and lungs must be functioning well enough to meet specific medical thresholds (confirm with trial site for exact measurements)
Who may not be able to join:
- You are pregnant or breastfeeding
- You have HIV infection or test positive for HIV
- You currently have an uncontrolled bacterial, viral, or fungal infection that is getting worse despite treatment
- You had an autologous (your own cells) stem cell transplant less than 12 months before enrolling
- You previously had an autologous transplant for the same disease being treated in this trial
- You have previously had an allogeneic (donor cells) stem cell transplant
- You have another active cancer (other than the one being treated here) within 12 months of enrolling
- You are unable to receive total body radiation (TBI), which is part of the treatment
- You currently need extra oxygen to breathe
- You have a fully tissue-matched (HLA-matched) related family member who is able to donate stem cells
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Mary Horowitz, MD, MS, Center for International Blood and Marrow Transplant Research
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants With Overall Survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.